CHILDREN'S ASTEPRO ALLERGY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHILDREN'S ASTEPRO ALLERGY (CHILDREN'S ASTEPRO ALLERGY).
Histamine H1 receptor antagonist; competitively inhibits histamine binding at H1 receptors on effector cells, reducing allergic symptoms.
| Metabolism | Hepatic via CYP3A4 and CYP2D6; first-pass metabolism; also metabolism by ester hydrolysis. |
| Excretion | Renal excretion accounts for approximately 40-60% of the administered dose as unchanged drug via glomerular filtration and active tubular secretion. Approximately 30-50% is eliminated in feces via biliary excretion, with the remainder as metabolites. |
| Half-life | The terminal elimination half-life is 12-15 hours (mean ~13.5 hours). This supports twice-daily dosing in children for sustained symptom control. |
| Protein binding | Approximately 88-92% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.5-2.6 L/kg, indicating extensive distribution into tissues including the nasal mucosa and lungs. |
| Bioavailability | Intranasal bioavailability is approximately 30-50% due to partial absorption in the nasal cavity and first-pass metabolism; systemic bioavailability is low relative to oral administration. |
| Onset of Action | Intranasal administration: Onset of action occurs within 1-2 hours, with maximum effect observed by 6-8 hours after the first dose. |
| Duration of Action | Duration of action is approximately 12 hours, allowing twice-daily dosing. Clinical efficacy is maintained with regular use; continuous daily dosing is recommended for optimal effect. |
| Molecular Weight | 381.9 |
Azelastine 0.1% nasal spray: 1 spray per nostril twice daily. Max 2 sprays per nostril per day.
| Dosage form | SPRAY, METERED |
| Renal impairment | No specific adjustment required; systemic absorption is minimal. |
| Liver impairment | No specific adjustment required. |
| Pediatric use | Children 6-12 years: 1 spray per nostril twice daily. Under 6 years: not recommended. |
| Geriatric use | No specific dose adjustment; use with caution due to possible increased somnolence. |
| 1st trimester | Avoid use during first trimester due to potential teratogenic effects based on animal studies with antihistamines; insufficient human data. |
| 2nd trimester | Use only if clearly needed; no evidence of fetal harm in second trimester, but limited data. |
| 3rd trimester | Avoid near term due to risk of respiratory depression and withdrawal symptoms in neonates. |
Clinical note
Comprehensive clinical and safety monograph for CHILDREN'S ASTEPRO ALLERGY (CHILDREN'S ASTEPRO ALLERGY).
| Placental transfer | Azelastine crosses the placenta in animal studies; human data limited. |
| Breastfeeding | Astepro (azelastine) is excreted into breast milk in small amounts; however, due to potential adverse effects such as drowsiness in infants, caution is advised. Monitor infant for sedation and irritability. Consider alternative antihistamines if possible. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to azelastine or any component of the formulation
| Precautions | Do not use with other products containing antihistamines or for children <6 years without consultation, May cause drowsiness or alertness impairment; caution when driving or operating machinery, Avoid concurrent use with alcohol or CNS depressants, Use with caution in renal or hepatic impairment, Use with caution in patients with narrow-angle glaucoma, symptomatic prostatic hypertrophy, bladder neck obstruction, asthma, or COPD |
| Food/Dietary | No specific food interactions. Alcohol may increase CNS depression effects. Avoid grapefruit juice as it may affect CYP450 metabolism (though azelastine is primarily metabolized by esterases and not CYP450, caution advised). |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Astepro Allergy (azelastine hydrochloride) is an H1-receptor antagonist. Animal studies with azelastine have shown no evidence of teratogenicity at oral doses up to 32 times the maximum recommended human daily inhalation dose. However, adequate and well-controlled studies in pregnant women are lacking. For first trimester: limited data, risk cannot be excluded; use only if clearly needed. Second and third trimesters: No known increased risk of fetal harm based on available data. Overall, classified as FDA Pregnancy Category C. |
| Fetal Monitoring | No specific routine monitoring is required. Assess maternal response to therapy and monitor for adverse effects such as somnolence or nasal irritation. In pregnancy, standard prenatal care should continue. No fetal monitoring is mandated. |
| Fertility Effects | No known adverse effects on human fertility. In animal studies, azelastine did not impair fertility at doses up to 32 times the maximum recommended human daily inhalation dose. However, limited data are available. |
| Clinical Pearls | CHILDREN'S ASTEPRO ALLERGY contains azelastine hydrochloride, an intranasal antihistamine. Onset of action is typically within 15-30 minutes. Bitter taste is common; instruct patients to avoid tilting head back immediately after administration. Use with caution in patients with renal impairment (CrCl <20 mL/min) due to risk of systemic accumulation. Do not administer concurrently with other antihistamines without monitoring for CNS depression. |
| Patient Advice | Shake bottle gently before each use. · Prime pump by spraying 4 times into air before first use or if not used for 3+ days. · Blow nose gently to clear nostrils before administration. · Insert nozzle into nostril, aim away from septum, and spray while breathing in through nose. · Do not tilt head back after spray to reduce bitter taste aftertaste. · Common side effects: bitter taste, headache, nasal burning/irritation, epistaxis. · Contact healthcare provider if symptoms worsen or do not improve after 3 days. · Store at room temperature, away from heat and direct light. |